Teacher Retirement System of Texas Grows Stake in Vaxart, Inc. (NASDAQ:VXRT)

Teacher Retirement System of Texas lifted its position in Vaxart, Inc. (NASDAQ:VXRT) by 19.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,439 shares of the biotechnology company’s stock after buying an additional 2,143 shares during the period. Teacher Retirement System of Texas’ holdings in Vaxart were worth $101,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Sowell Financial Services LLC boosted its stake in shares of Vaxart by 1,194.8% in the 1st quarter. Sowell Financial Services LLC now owns 5,179 shares of the biotechnology company’s stock worth $36,000 after buying an additional 4,779 shares during the last quarter. BNP Paribas Arbitrage SA boosted its stake in shares of Vaxart by 32.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 7,383 shares of the biotechnology company’s stock worth $45,000 after buying an additional 1,805 shares during the last quarter. Kestra Private Wealth Services LLC purchased a new position in shares of Vaxart in the 1st quarter worth $79,000. GSA Capital Partners LLP lifted its position in Vaxart by 86.2% during the first quarter. GSA Capital Partners LLP now owns 19,310 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 8,939 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Vaxart by 127.1% during the first quarter. JPMorgan Chase & Co. now owns 20,324 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 95,296 shares in the last quarter. Hedge funds and other institutional investors own 28.32% of the company’s stock.

Shares of Vaxart stock opened at $7.87 on Tuesday. The stock’s 50-day simple moving average is $8.39 and its 200-day simple moving average is $7.41. Vaxart, Inc. has a 52 week low of $3.50 and a 52 week high of $24.90. The company has a market capitalization of $966.58 million, a price-to-earnings ratio of -16.40 and a beta of 0.31.

Vaxart (NASDAQ:VXRT) last announced its quarterly earnings data on Thursday, August 5th. The biotechnology company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. Vaxart had a negative return on equity of 34.27% and a negative net margin of 4,363.92%. Analysts forecast that Vaxart, Inc. will post -0.68 earnings per share for the current year.

In other news, SVP Sean Tucker sold 4,172 shares of Vaxart stock in a transaction dated Tuesday, August 10th. The stock was sold at an average price of $10.20, for a total value of $42,554.40. Following the sale, the senior vice president now directly owns 333 shares of the company’s stock, valued at $3,396.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 7,773 shares of company stock worth $73,344 over the last ninety days. Insiders own 3.10% of the company’s stock.

Several equities analysts recently weighed in on the company. Jefferies Financial Group assumed coverage on Vaxart in a research report on Thursday, June 24th. They set a “buy” rating and a $13.00 target price on the stock. Zacks Investment Research downgraded Vaxart from a “buy” rating to a “hold” rating in a research report on Thursday, September 2nd. B. Riley downgraded Vaxart from a “buy” rating to a “neutral” rating and lowered their target price for the company from $13.00 to $9.00 in a research report on Tuesday, June 29th. Finally, Piper Sandler started coverage on Vaxart in a research report on Friday, June 11th. They issued an “overweight” rating and a $18.00 price objective on the stock.

Vaxart Profile

Vaxart, Inc operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.

Recommended Story: What is a resistance level?

Want to see what other hedge funds are holding VXRT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxart, Inc. (NASDAQ:VXRT).

Institutional Ownership by Quarter for Vaxart (NASDAQ:VXRT)

Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.